USAMRMC

AcronymDefinition
USAMRMCUnited States Army Medical Research and Materiel Command
References in periodicals archive ?
USAMRMC increased contract awards to small businesses from $285 million in fiscal 2004 to $383 million in fiscal 2005, or about 48 percent of the command's contract awards.
USAMRMC is the Army's medical materiel developer, with lead agency responsibility for medical research, product development, technology assessment and rapid prototyping, medical logistics management and health facility planning and medical information management and technology.
Complete N/A USAMRMC Institutional Review Board: Human Subjects Research Initial Protocol Application Protocol Prepared using the current version of the templates provided by RLNO Part A 1.
The USAMRMC Office of the Staff Judge Advocate (OSJA) supervises and manages the administration, control, and coordination of all patent, copyright, and trademark activities within MEDCOM, as well as serving as the technology transfer legal technical channel supervisor for all MEDCOM units.
For example, the USAMRMC instructs extramural partners to include, after their own Common Rule policy, language in their consent forms informing subjects of the availability of no-cost medical care at Army medical treatment facilities, in accordance with Army Regulation 70-25 (16) and paragraph 3-56 of Army Regulation 40-400, (31) and of a process to seek reimbursement (nonguaranteed) for out-of-pocket, research-related medical expenses incurred.
Army Medical Research and Materiel Command, or USAMRMC, for development of ARX-04, a sufentanil tablet product candidate for the treatment of moderate-to-severe acute pain in a range of ambulatory environments.
7 million in reimbursement for work associated with the USAMRMC grant.
Army Medical Research and Materiel Command, or USAMRMC, for development of ARX-04, a sufentanil NanoTab product candidate for the treatment of moderate-to-severe acute pain in a range of military and ambulatory environments.
Our CRADA with USAMRMC is the first in a series of outcome and economic studies that will demonstrate the value of OVA1 and establish its benefit in improving health system efficiency.
The clinical study and associated research activities for ARX-04 are funded by a grant from USAMRMC.
These regulatory-compliant and validated systems support USAMRMC clinical researchers in the development of the FDA-regulated drugs, vaccines, biologics, and devices.
AcelRx recently announced positive top-line results for a Phase 2 trial for ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from USAMRMC.